Elnakish Mohammad T, Ahmed Amany A E, Mohler Peter J, Janssen Paul M L
Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA ; Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, USA ; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
Oxid Med Cell Longev. 2015;2015:854265. doi: 10.1155/2015/854265. Epub 2015 Jun 4.
Cardiac hypertrophy is the most documented cardiomyopathy following hyperthyroidism in experimental animals. Thyroid hormone-induced cardiac hypertrophy is described as a relative ventricular hypertrophy that encompasses the whole heart and is linked with contractile abnormalities in both right and left ventricles. The increase in oxidative stress that takes place in experimental hyperthyroidism proposes that reactive oxygen species are key players in the cardiomyopathy frequently reported in this endocrine disorder. The goal of this review is to shed light on the effects of thyroid hormones on the development of oxidative stress in the heart along with the subsequent cellular and molecular changes. In particular, we will review the role of thyroid hormone-induced oxidative stress in the development of cardiomyocyte hypertrophy and associated cardiac dysfunction, as well as the potential effectiveness of antioxidant treatments in attenuating these hyperthyroidism-induced abnormalities in experimental animal models.
心脏肥大是实验动物甲状腺功能亢进后记录最多的心肌病。甲状腺激素诱导的心脏肥大被描述为一种相对的心室肥大,累及整个心脏,并与左右心室的收缩异常有关。实验性甲状腺功能亢进时发生的氧化应激增加表明,活性氧是这种内分泌疾病中常见的心肌病的关键因素。本综述的目的是阐明甲状腺激素对心脏氧化应激发展的影响以及随后的细胞和分子变化。特别是,我们将综述甲状腺激素诱导的氧化应激在心肌细胞肥大和相关心脏功能障碍发展中的作用,以及抗氧化治疗在减轻实验动物模型中这些甲状腺功能亢进诱导的异常方面的潜在效果。